1. No category

Boston Park Plaza Hotel
June 13-16, 2015
Preliminary Program
(Current as of 5/19/2015)
Organizing Institutions
Saturday, June 13, 2015
5:00pm-8:00pm
Registration
5:30pm-7:30pm
Welcome Reception
7:30pm-8:15pm
Opening Speaker:
Robert Martuza, MD (Massachusetts General Hospital)
25 years of genetically engineered viruses for cancer
8:15pm-9:00pm
Opening Speaker:
Gordon Freeman, PhD (Dana-Farber Cancer Institute)
Immune checkpoint inhibition, T cell exhaustion and cancer
Sunday, June 14, 2015
7:30am-6:30pm
Registration
7:30am-8:30am
Breakfast
8:30am-10:30am
Session 1: Clinical Trials I
Moderators: Eva Galanis, MD, Mayo Clinic &
James Markert, MD, UAB School of Medicine
8:30am-8:50am
Eva Galanis, MD Clinical Trials with oncolytic measles
8:50am-9:10am
James Markert, MD Clinical Trials with oncolytic HSV and reovirus for
GBM
9:10am-9:25am
Mitesh J. Borad (O-1)
Phase I Trial of Vesicular Stomatitis Virus with Human Beta Interferon
Insert in Patients with Primary and Metastatic Liver Cancers
9:25am-9:40am
S.B. Onikienko (O-2)
Oncolytic Virotherapy Combination Strategies using innovative Biologic,
Laser and Nuclear Technologies
9:40am-9:55am
Kerry Fisher (O-3)
Enadenotucirev is a well-tolerated group B oncolytic adenovirus that can
access and infect tumour cells in cancer patients following intravenous
delivery
9:55am-10:10am
Clemens MF Dirven (O-4)
Preliminary results of a phase I clinical trial with the Delta24RGD
oncolytic adenovirus administered by CED in patients with recurrent
glioblastoma
10:10am-10:25am
Karsten Geletneky (O-5)
Favorable response of patients with glioblastoma at second recurrence
to repeated injection of oncolytic parvovirus H-1, in particular in
combination with bevacicumab”
10:30am -11:00am
Coffee Break
11:00am -1:00pm
Session 2: Mechanisms of OV Killing
Moderators: Len Seymour, PhD, University of Oxford &
David Stojdl, PhD, CHEO Research Institute
11:00am-11:20am
Len Seymour, PhD
Mechanisms of inflammatory cell death
11:20am-11:35am
Michael C. Brown (O-6)
Targeting glioblastoma with an oncolytic poliovirus: a clinical update
and new insights into tumor selective cytotoxicity
11:35am-11:50am
Grant McFadden (O-7)
Ex vivo virotherapy of allogeneic stem cell transplants with oncolytic
Myxoma Virus eliminates pre-existing residual myeloma in
immunocompetent recipients
11:50am-12:05pm
Amber Miller (O-8)
Hemodynamic manipulations affect intratumoral delivery and efficacy of
systemically administered oncolytic virotherapy
12:05pm-12:20pm
Anne Kleijn (O-9)
Comparison of 5 Oncolytic Viruses on Patient-derived glioblastoma stem
cell cultures reveals virus-specific responder/non-responder profiles
12:20pm-12:35pm
Samuel Workenhe (O-10)
Genome-wide lentiviral shRNA screen identifies Serine-arginine Rich
Splicing Factor 2 as a determinant of oncolytic virus activity
12:35pm-12:50pm
Juan C. Corredor (O-11)
Effects of N-myc overexpression on oncolytic vesicular stomatitis virus
tropism to high-risk neuroblastoma cells
1:00pm-2:15pm
Lunch
2:15pm-3:30pm
Session 3: Combination Therapies
Moderators: Martine Lamfers, PhD, Erasmus MC &
Hiroaki Wakimoto, MD, Massachusetts General Hospital
2:15pm-2:30pm
Shawn Beug (O-12)
Potentiation of Smac mimetics cytotoxicity by cytokine-armed oncolytic
viruses
2:30pm-2:45pm
Antonio Marchini (O-13)
Oncolytic parvovirus H-1PV and the BH3 mimetic ABT-737 synergize
against solid tumours
2:45pm-3:00pm
Jianfang Ning (O-14)
PARP inhibitors sensitize glioblastoma stem cells to oncolytic herpes
simplex virus therapy
3:00pm-3:15pm
Michelle J Wilkinson (O-15)
Pre-clinical evaluation of oncolytic virotherapy delivered by isolated limb
perfusion, alone and in combination with chemotherapy, radiotherapy
and surgical resection
3:15pm-3:30pm
Keri A. Streby (O-16)
Enhanced Targeted 131I-mIBG Radionuclide Therapy with Oncolytic
HSV1716 and NAT Gene Therapy: a Novel Approach to Neuroblastoma
3:30pm-4:10pm
Coffee Break
4:10pm-6:20pm
Session 4: Imaging / Monitoring / Toxicology
Moderators: Kah Whye Peng, PhD, Mayo Clinic &
Tomoki Todo, MD, PhD, University of Tokyo
4:10pm-4:30pm
Kah Whye Peng, PhD
Systemic administration of VSV-IFN-NIS: safety and efficacy insights
from a mouse model
4:30pm-4:45pm
Julia Davydova (O-17)
Oncolytic Adenovirus for Radioiodine Therapy of Non-Thyroid Cancer
4:45pm-5:00pm
Darshini Kuruppu (O-18)
HSV-1 Oncolysis Therapy for Breast Cancer Meningeal Metastases
5:00pm-5:15pm
Christopher D. Richardson (O-19)
PVRL4 (Nectin-4) is a marker for metastatic breast cancer and a target
for oncolytic therapy using measles and VSV-measles chimeric viruses
5:15pm-5:30pm
Pin-Yi Wang (O-20)
Neuroblastomas Vary Widely in Their Antitumor Responses to Herpes
Virotherapy Unrelated to Virus Receptors, Susceptibility and
Permissivity
5:30pm-5:45pm
Kathryn Ottolino-Perry (O-21)
Radiovirotherapy of Colorectal Peritoneal Carcinomatosis using a
Somatostatin Receptor-Expressing Oncolytic Virus Combined with
177-Lu-DOTATOC
5:45 pm-6:05pm
Tomoki Todo, MD, PhD
Clinical Trials with oncolytic HSV G47∆
6:10pm-8:00pm
Hors d'oeuvres & Drinks
8:00pm-10:00pm
Poster Session I
Monday, June 15, 2015
7:30am-5:00pm
Registration
7:30am- 8:30am
Breakfast
8:30am -10:30am
Session 5: Engineering 1
Moderators: Noriyuki Kasahara, MD PhD, University of Miami &
Paola Grandi, PhD, University of Pittsburgh
8:30am-8:50am
Noriyuki Kasahara, MD PhD
TBD
8:50am-9:10am
Dillon Betancourt (O-22)
Retargeting Vesicular stomatitis virus (VSV) as an oncolytic to treat
Human T-cell lymphotropic Virus 1 (HTLV1) associated Adult T-cell
leukemia (ATL)
9:10am-9:25am
Paola Sette (O-23)
Arming a tumor targeted oncolytic herpes simplex virus type 1 with
matrix metalloproteinase 9 for enhanced vector distribution and killing
activity
9:25am-9:40am
Munitta Muthana (O-24)
Use of magnetic resonance targeting to steer OV-loaded cell-based
therapies to tumor sites in vivo
9:40am-9:55am
Carlos Alberto Fajardo (O-25)
Arming oncolytic adenoviruses with bi-specific T-cell engagers to
improve antitumor immune responses
9:55am-10:10am
Takafumi Nakamura (O-26)
Deletions of both vaccinia growth factor and O1 protein genes enhance
therapeutic index of oncolytic vaccinia virus
10:15am -11:00am
Coffee Break
11:00am-1:00pm
Session 6: Engineering 2
Moderators: Samuel Rabkin, PhD, Massachusetts General Hospital &
D. Grant McFadden, PhD, University of Florida
11:00am-11:15am
Carolina S. Ilkow (O-27)
Tailored Oncolytic viral Therapeutics for Pancreatic Cancer
11:15am-11:30am
Autumn J. Ruiz (O-28)
MicroRNA-Based Multi-Tissue Detargeted Mengovirus for Multiple
Myeloma
11:30am-11:45am
Valery Z. Grdzelishvili (O-29)
An unexpected inhibition of antiviral signaling by virus-encoded tumor
suppressor p53 in pancreatic cancer cells
11:45am-12:00pm
Yaohe Wang (O-30)
Development of a novel tumour-targeted oncolytic Ad11 virus armed
with IL-15R/IL-15 fused gene for treatment of lung cancer
12:00pm-12:15pm
Masato Yamamoto (O-31)
Two applications of infectivity selective oncolytic adenoviruses: Systemc
therapy and cancer stem cell targeting
12:15pm-12:30pm
Margaret R. Duffy (O-32)
Actin resistant DNAse I expression from oncolytic adenovirus
Enadenotucirev enhances its intratumoural spread and reduces tumour
growth
12:30pm-5:00pm
Afternoon Free
5:00pm-5:40pm
Keynote Speaker:
Rakesh Jain, PhD (Massachusetts General Hospital)
Reengineering the tumor microenvironment to improve delivery
and efficacy of therapeutics
5:00pm-6:30pm
Hors d'oeuvres & Drinks (Concurrent with Session 7)
6:00pm-8:00pm
Session 7: Immunology 1
Moderators: Brian Lichty, PhD, McMaster University &
Alan Melcher, PhD, University of Leeds
6:00pm-6:20pm
Brian Lichty, PhD
Driving Large T Cell Responses Using Oncolytic Vaccines
6:20pm-6:40pm
Alan Melcher, PhD
Maximising Anti-Tumour Immune Priming With Reovirus Oncolytic
Virotherapy
6:40pm-6:55pm
Christine E. Engeland (O-33)
Immune checkpoint modulation enhances oncolytic Measles virus
therapy
6:55pm-7:10pm
Gough Au (O-34)
Combination of a novel oncolytic immunotherapeutic agent, CAVATAKTM
(Coxsackievirus A21) and immune-checkpoint blockade significantly
reduces tumor growth and improves survival in an immune competent
mouse melanoma model
7:10pm-7:25pm
Grauwet Korneel (O-35)
Alphaherpesvirus US3 protein kinase protects infected cells from NK cellmediated lysis via increased binding of the inhibitory NK cell receptor
CD300a
7:25pm-7:40pm
Matthew Mulvey (O-36)
Arming an Oncolytic HSV1 with a TAP Inhibitor Improves Therapeutic
Efficacy
7:40pm-7:55pm
Ahmed A. Mostafa (O-37)
The use of immune checkpoint blockade and immune modulator to
enhance the efficiency of oncolytic viral therapy
8:00pm-10:00pm
Poster Session II
Tuesday, June 16, 2015
7:30am-5:00pm
Registration
7:30am-8:30am
Breakfast
8:30am-10:30am
Session 8: Immunology 2
Moderators: Nino Chiocca, MD, PhD, Brigham & Women’s Hospital &
Glen Barber, PhD, University of Miami
8:30am-8:50am
Glen Barber, PhD
TBA
8:50am-9:10am
Richard Vile. PhD
TBA
9:10am-9:25am
Matteo Riva (O-38)
Combining oncolytic virotherapy with DC-mediated immunotherapy in
the treatment of high grade glioma
9:25am-9:40am
Steve H. Thorne (O-39)
Immune optimized oncolytic vaccinia virus displays dramatically
enhanced therapeutic activity
9:40am-9:55am
Siri Tähtinen (O-40)
Oncolytic adenovirus improves anti-tumor efficacy of adoptive T-cell
therapy by breaking tumor tolerance
9:55am-10:10am
Aladar A. Szalay (O-41)
Combination Immunotherapy with oncolytic vaccinia virus and
checkpoint inhibitor following local tumor irradiation
10:10am-10:25am
Karishma Rajani (O-42)
Combination therapy of Reovirus and PD-1 blockade effectively
establishes tumor control via innate and adaptive immune responses
10:30am-11:00am
Coffee Break
11:00am-1:00pm
Session 9: OV and Microenvironment
Moderators: John Bell, PhD, Ottawa Hospital Research Institute &
Juan Fueyo, MD, MD Anderson Cancer Center
11:00am-11:20am
John Bell, PhD
Understanding virus: cell interactions in the tumour niche: an
opportunity to enhance virus therapy
11:20am-11:40am
Juan Fueyo, PhD
Delta-24-RGDOX: an oncolytic adenovirus enhances anti-glioma
immunity expressing the immune checkpoint co-stimulator OX40 ligand
11:40am-11:55am
Jennifer Altomonte (O-43)
Increased viral replication due to cross-talk between tumor and stellate
cells indicate oncolytic VSV as a potent therapy for stromal-rich tumors
11:55am-12:10pm
Jamie Merchan (O-44)
Stromal selective targeting by murine uPAR retargeted oncolytic
measles virus delays breast cancer progression
12:10pm-12:25pm
Prem Seth (O-45)
Oncolytic Adenovirus Expressing Decorin: Co-Targeting the Tumor Cells
and the Microenvironment for the Treatment of Breast Cancer Bone
Metastases
12:25pm-12:40pm
Trevor G. Shepherd (O-46)
Ovarian Tumour cell heterogeneity impacts maraba virus infection and
oncolytic efficacy
12:40pm-12:55pm
Darren Shafren (O-53)
Characterisation of the oncolytic kinetics of the immunotherapeutic
agent, CAVATAK, delivered intratumORALly in patients with advanced
malignant melanoma.
1:00pm-2:00pm
Working Lunch
1:30pm-2:50pm
Session 10: Experiences in Biotech Venture (Nino moderates)
Speakers: Matt Mulvey, PhD, Frank Tufaro, PhD, David Kirn, MD,
Robert Coffin, MD
1:30pm-1:45pm
Matt Mulvey, (Benevir): The starting phases of a biotech (preclinical)
1:45pm-2:00pm
Frank Tufaro, PhD, (DNAtrix): The middle phases of a biotech (phase Iphase II clinical trials)
2:00pm-2:15pm
David Kirn, MD, (4D): What happens as biotech companies mature?
2:15pm-2:30pm
Rob Coffin: The Endgame
2:30pm-2:50pm
Panel discussion
3:00pm-5:00pm
Session 11: Clinical Trials II
Moderators: Stephen J. Russell, MD, PhD, Mayo Clinic &
Timothy P. Cripe, MD, PhD, Nationwide Children’s
Hospital
3:00pm-3:15pm
Robert H. I. Andtbacka (O-52)
Survival, safety, and response patterns in a phase 1b multicenter trial of
talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously
untreated, unresected stage IIIB-IV melanoma
3:15pm-3:30pm
Timothy P. Cripe, MD, PhD
The Pros of Virotherapy Trials in Children: Progress, Problems, and
Promise
3:30pm-3:45pm
Douglas J Jolly (O-48)
Retroviral Replicating Vectors as therapeutic agents: Update on
preclinical and clinical safety and efficacy
3:45pm-4:00pm
Hideki Kasuya (O-49)
Potential Therapeutic Effectivity for Combination of HF10 with Erlotinib
and Gemcitabine
4:00pm-4:15pm
Ulrich M. Lauer (O-50)
Final results of the first phase I study of intraperitoneal administration
of GL-ONC1, a marker gene modified vaccinia virus, in patients with
peritoneal carcinomatosis”
4:15pm-4:30pm
Hardev S. Pandha (O-51)
Phase I/II STORM study: Intravenous delivery of a novel oncolytic
immunotherapy agent, CAVATAK, in advanced cancer patients
4:30pm-4:50pm
Stephen J. Russell, MD
TBA
4:50pm-5:00pm
Closing Remarks
6:00pm-6:30pm
Buses start – Boston Park Plaza to Rowe’s Wharf (run until 6:45pm)
7:00pm-9:30pm
Gala Celebration: Odyssey Dinner Cruise – Boston Harbor
7:00pm – 9:30pm – Cruise Boston Harbor
Golden Virus Award Presentation: Lifetime Achievement Award for
Oncolytics awarded to Dr. Robert Martuza
9:30pm
Buses start – Rowe’s Wharf to Boston Park Plaza
Busses will run until all attendees have departed the Odyssey